Meetings

MONTREAL – April 24, 2026 – New data analyzing more than 20,000 patients from three major NIH studies show that elevated Lipoprotein(a) [Lp(a)] is associated with residual cardiovascular risk and warrants aggressive risk reduction. Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions and Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

MONTREAL – April 24, 2026 – The first comparative analysis from the ENGULF (A Safety and Feasibility Single-Arm Study of a Novel Catheter Thrombectomy Device For the Treatment of Pulmonary Embolism) trial shows that using blood return during continuous aspiration thrombectomy dramatically reduces blood loss by 97%, while maintaining hemodynamic efficacy and improving procedural efficiency. Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal. 

MONTREAL – April 24, 2026 – Findings from the North American COVID-19 Myocardial Infarction (NACMI) registry demonstrate significantly higher one-year mortality rates in patients with COVID-19 and ST-elevation myocardial infarction (STEMI) compared to patients with STEMI alone. This registry is the first study to describe long-term outcomes in patients with STEMI and COVID-19. Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

MONTREAL – April 24, 2026 – Results from a new analysis show that patients with mitral annular calcification (MAC) who undergo minimally invasive mitral transcatheter edge-to-edge repair (M-TEER) experience similar reductions in mitral regurgitation (MR) and improvement in quality of life compared to those seen in patients without calcification. Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

MONTREAL – April 24, 2026 – Results from the largest real-world propensity-matched comparison to date show that radial-to-peripheral (R2P) access achieves procedural success rates comparable to traditional common femoral artery (CFA) access for lower extremity peripheral artery disease (PAD) revascularization. However, six-month major adverse limb events (MALE) were higher in the R2P group, predominantly driven by target vessel revascularization (TVR). Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

How do we move from biomarkers to clinical decisions in solid tumors? And how is neoadjuvant immunotherapy reshaping rectal cancer care? These are the questions driving our 6th Youth Scholar Salon — an open, live-streamed academic forum held by LabMed Discovery editorial team.

 

Speaker 1: Dr. Yang Zhengyang will present “Clinical Evidence Accumulation and Standardized Practice of Neoadjuvant Immunotherapy for Rectal Cancer — From Evidence to Guidelines”, from four perspectives: background and challenges, clinical efficacy validation, mechanism exploration, and evidence integration for guidelines.

 

Speaker 2: Dr. Cheng Xi will share “From Biomarkers to Clinical Decision-Making: Construction of a Predictive System for Targeted Therapy Sensitivity in Solid Tumors”, covering three parts: the research advantages of surgeons, mechanistic insights into anlotinib, preliminary study of anlotinib in CRC application.

 

Open to all, no prior knowledge needed. Just bring your curiosity. Hope to see you there

MONTREAL – April 23, 2026 – Researchers presented data on the secondary endpoints from STEMI-DTU (ST-segment Elevation Myocardial Infarction Door-To-Unload) today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

MONTREAL – April 23, 2026 – New research found that public interest in Transcatheter Aortic Valve Replacement (TAVR) increased substantially over the last decade, with Google search volume rising by 340% from 2015 to 2025, while searches for SAVR (Surgical Aortic Valve Replacement) declined by 42%. These trends parallel a shift in practice, as clinicians doubled TAVR use between 2015 and 2021. Researchers presented this data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

Researchers presented the findings today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

MONTREAL – April 23, 2026 – A new sub-study suggests that using a sirolimus-eluting balloon (SEB), a drug-coated balloon, can reduce the number of stents a patient may need, making it a safe and effective way to treat certain heart attacks or unstable chest pain. Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

MONTREAL – April 23, 2026 – Findings from the AltaValve™ Early Feasibility Study suggest that patients with a leaky mitral valve have sustained clinical benefits one year following atrial fixation Transcatheter Mitral Valve Replacement (TMVR). Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.